Caprock Group’s TG Therapeutics TGTX Stock Holding History

Caprock Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,487	Closed	-$213K	–	572
2021 Q2	$213K	Buy	+5,487	New	+$215K	0.02%	485

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caprock Group's TGTX Position: Q3 2021 in Review

Caprock Group sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 5,487 shares — an estimated $213K sold.

Caprock Group first reported a position in TGTX in Q2 2021 and held it in 1 quarter. The position peaked at $213K in Q2 2021. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

Caprock Group reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
Caprock Group sold 5,487 TG Therapeutics shares in Q3 2021, an estimated $213K.
Caprock Group first reported a position in TG Therapeutics in Q2 2021 and held it in 1 quarter.
Caprock Group's TG Therapeutics position peaked at $213K in Q2 2021.
222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Caprock Group's 13F filing for Q3 2021, filed 7 Oct 2021.